People with cystic fibrosis (pwCF) have an altered gastrointestinal microbiome. These individuals also demonstrate propensity toward developing small intestinal bacterial overgrowth (SIBO). The dysbiosis present has intestinal and extraintestinal implications, including potential links with the higher rates of gastrointestinal malignancies described in CF. Given these implications, there is growing interest in therapeutic options for microbiome modulation. Alternative therapies, including probiotics and prebiotics, and current CF transmembrane conductance regulator gene modulators are promising interventions for ameliorating gut microbiome dysfunction in pwCF. This article will characterize and discuss the current state of knowledge and expert opinions on gut dysbiosis and SIBO in the context of CF, before reviewing the current evidence supporting gut microbial modulating therapies in CF.
Using the Occupational Stress Indicator, the results from this study provided a comparative overview of Australian and UK hospital workers’ perceived responses to organizational sources of pressure, use of coping strategies plus outcomes of job satisfaction, mental and physical ill health. The broad picture that emerged was that the Australian hospital workers appeared to have a more favourable working environment as their organization presented fewer sources of pressure. Despite lower levels of contributory pressure, it was apparent that Australian hospital workers perceived similar long‐term outcomes to organizational sources of pressure as the UK hospital worker sample. The Australian hospital workers reported significantly higher perceived physical ill health, and second, similar levels of mental ill health and job satisfaction when compared to the UK hospital workers. In addition, the Australian hospital workers reported increased use of coping strategies. The discussion takes into consideration the context and time frame of the two operating environments.
Cystic fibrosis (CF) patients experience higher risks of colorectal cancer but the pathogenesis is unclear. In the general population, polyketide synthase-positive (pks+) E. coli is implicated in intestinal carcinogenesis via the production of colibactin; however, the relevance in CF is unknown. In this study, we investigate pks+E. coli prevalence in CF and potential associations between pks+E. coli, gastrointestinal inflammation, and microbiome dynamics with fecal calprotectin and 16SrRNA gene taxonomic data. Cross-sectional analysis demonstrated no difference in pks+E. coli carriage between CF patients and healthy controls, 21/55 (38%) vs. 26/55 (47%), p = 0.32. Pks+E. coli was not associated with significant differences in mean (SD) calprotectin concentration (124 (154) vs. 158 (268) mg/kg; p = 0.60), microbial richness (159 (76.5) vs. 147 (70.4); p = 0.50) or Shannon diversity index (2.78 (0.77) vs. 2.65 (0.74); p = 0.50) in CF. Additionally, there was no association with exocrine pancreatic status (p = 0.2) or overall antibiotic use (p = 0.6). Longitudinally, CF subjects demonstrated intra-individual variation in pks+E. coli presence but no significant difference in overall prevalence. Future investigation into the effects of repeat exposure on risk profile and analysis of older CF cohorts is necessary to identify if associations with colorectal cancer exist.
Cystic fibrosis (CF) patients experience higher risks of colorectal cancer, but pathogenesis is unclear. In the general population, polyketide synthase-positive (pks+) E. coli is impli-cated in intestinal carcinogenesis via production of colibactin, however relevance in CF is unknown. We investigated pks+ E. coli prevalence in CF at baseline and longitudinally, performing PCR on stool DNA extracts. Potential associations between pks+ E. coli and gastrointestinal inflammation or microbiome dynamics were analysed using faecal calprotectin and 16SrRNA gene taxonomic data. At baseline, no difference in pks+ E. coli carriage was identified between CF and healthy controls, 21/55(38%) vs 26/55(47%), p=0.32. Pks+ E. coli was not associated with significant differences in mean (SD) calpro-tectin concentration (124(154) vs 158(268) mg/kg; p=0.60), microbial richness (159(76.5) vs 147(70.4); p=0.50) or Shannon diversity index (2.78(0.77) vs 2.65(0.74); p=0.50) in CF. Lon-gitudinally, subjects demonstrated intra-individual variation in pks+ E. coli presence, however no significant difference in overall prevalence was observed. Thus, intesti-nal pks+ E. coli prevalence was not different between CF and healthy controls, nor associ-ated with differences in gut microbial profile or inflammation. Investigating effects of re-peat exposure on risk profile and analysis of older CF cohorts is necessary to identify if associations with colorectal cancer exist.
Background: In a therapeutic partnership, physicians rely on patients to describe their health conditions, join in shared decision-making, and engage with supported self-management activities. In shared care, the patient, primary care, and specialist services partner together using agreed processes and outputs for the patient to be placed at the centre of their care. However, few empirical studies have explored physicians’ trust in patients and its implications for shared care models. Aim: To explore trust in patients amongst general practitioners (GPs), and the impacts of trust on GPs’ willingness to engage in new models of care, such as colorectal cancer shared care. Methods: GP participants were recruited through professional networks for semi-structured interviews. Transcripts were integrity checked, coded inductively, and themes developed iteratively. Results: Twenty-five interviews were analysed. Some GPs view trust as a responsibility of the physician and have a high propensity for trusting patients. For other GPs, trust in patients is developed over successive consultations based on patient characteristics such as honesty, reliability, and proactivity in self-care. GPs were more willing to engage in colorectal cancer shared care with patients with whom they have a developed, trusting relationship. Conclusions: Trust plays a significant role in the patient’s access to shared care. The implementation of shared care should consider the relational dynamics between the patient and health care providers.